ClinicalTrials.gg
RecruitingNCT06874335Updated Jul 9, 2026

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

A Phase 1 interventional study of BHV-1530 and Cemiplimab in Solid Tumor, sponsored by Biohaven Therapeutics Ltd.. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Biohaven Therapeutics Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

02

Conditions studied

  • Solid Tumor

Keywords

  • FGFR3-targeting ADC
  • antibody-drug conjugate
  • FGRF3
  • ADC
  • FGFR3 alteration
  • advanced cancers
  • cemiplimab
03

In context

Lead sponsor

Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved
  2. Age greater than or equal to 18 years
  3. Participants consent to provide tumor tissue collected prior to study treatment, preferably from a performed after their last anticancer therapy and within 90 days of the start of study treatment. An older archival sample may be acceptable with Sponsor approval.
  4. Participants must have progressed following, are intolerant of, or have no available standard-of-care therapy.
  5. Patients with or cytologically confirmed locally advanced/ solid tumors as outlined below:

    • Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 monotherapy):

      • Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.

        • Tumors originating from the salivary glands, or unknown primary sites are not eligible.
      • Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion).
    • Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 in combination with cemiplimab):

      • Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.

        • Tumors originating from the salivary glands, or unknown primary sites are not eligible.
      • Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion).

    Participants must have received ≤ 2 prior lines of systemic anti-cancer therapy which may include at most one prior anti-programmed cell death protein 1 () (programmed death-ligand 1 [PD-L1]) therapy for advanced/metastatic disease.

    Dose Optimization Cohorts (BHV-1530 monotherapy):

    oParticipants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra)..

  6. Measurable advanced or metastatic tumors per 1.1 criteria
  7. Patients must exhibit an (ECOG) performance status of 0 or 1
  8. Acceptable liver function:

    • ≤ 1.5 × (ULN). Participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
    • , ALT, and alkaline phosphatase ≤ 2.5 × ULN (if liver metastases are present, then ≤ 5 × ULN is allowed)
  9. Acceptable renal function:

    • Serum creatinine ≤1.5 × ULN, or ≥50 mL/min as calculated using the modified Cockcroft-Gault equation; confirmation of creatinine clearance is only required when creatinine is >1.5 × ULN; 24-hour urine collection is allowed, but not required
  10. Acceptable hematologic status:

    • Blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility
    • greater than or equal to 1500/mm3. Participants with known Duffy null phenotype who have absolute neutrophil count ≥ 1,200/mm3 may be enrolled
    • count greater than or equal to 100,000 mm3
    • greater than or equal to 9 g/dL
    • (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
  11. A negative urine or serum pregnancy test (if a woman of );
  12. Women of childbearing potential and men must agree to use adequate prior to study entry, for the duration of study participation and for 7 months (for women) or 4 months (for men) after the last dose of study drug.

General Exclusion Criteria:

  1. Prior treatment with antibody drug conjugate (ADC) with a topoisomerase-I inhibitor payload. Prior direct treatment with topoisomerase inhibitor (e.g., irinotecan, topotecan, belotecan, nano-liposomal irinotecan) are not exclusionary.
  2. Participant has intercurrent disease including, but not limited to:

    • Class III or IV heart failure
    • Myocardial infarction, unstable angina, or stroke ≤ 6 months prior to C1D1
    • Newly diagnosed thromboembolic events that require therapeutic intervention over the last 4 months prior to C1D1 (participants with stable control of lower limb deep venous thrombosis over at least 1 months are allowed, and participants with incidental, asymptomatic pulmonary embolism and clinically stable for at least 1 month prior to C1D1 are allowed)
    • Severe aortic stenosis
    • Uncontrolled arrhythmia
    • Symptomatic pericardial effusion
    • Congenital long syndrome
    • A mean of Fredericia's formula-QT corrected interval (QTcF) prolongation to >470 msec based on a triplicate 12-lead
    • Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) or diabetes ( ≥9.0%)
    • (LVEF) \<45% determined by echocardiogram or multiple gated acquisition scan (MUGA)
  3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  4. Primary central nervous system (CNS) tumors, current or previously treated or known active .

    NOTE: Participants with previously treated, clinically stable, radiologically stable brain metastases maybe eligible

  5. Pregnant or nursing women
  6. Any standard cancer therapy (e.g., chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone-only radiation therapy. Any major surgical procedure within 6 weeks prior to C1D1
  7. Participants have not recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. If the participant has an ongoing, stable, chronic Grade 2 toxicity they may be eligible after discussion with Sponsor on a case-by-case basis
  8. Any clinically significant corneal or retinal abnormality that may increase the risk of eye toxicity
  9. Known active infection with (HIV), human T-cell leukemia virus, type 1 (HTLV-1), virus (HBV), or virus (HCV), if allowed by local regulations:

    • Participants with hepatitis B (hepatitis B virus surface antigen [HbsAg] positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Participants with HCV with undetectable virus after treatment are eligible. Participants with a prior history of hepatitis B virus are eligible if quantitative polymerase change reaction for hepatitis B virus DNA is negative
    • Participants with human immunodeficiency virus (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; however, participants who have had HIV infection and who have a cluster of differentiation 4 (CD4) + T cell count >350 cells/μL and no history of an AIDS-defining illness are eligible for entry
  10. Has an active second . Note: participants with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with tumors cured with radiotherapy or surgery with low risk of recurrence (e.g., non melanoma skin cancer, histologically confirmed complete excision of carcinoma in situ) are allowed
  11. Participants who in the opinion of the Investigator will not be able to adhere to the schedule of assessments and/or may have difficulties complying with the treatment regimen or are unwilling or unable to comply with procedures required in this protocol
  12. Known sensitivity to BHV-1530 or any of the in BHV-1530;
  13. History of (noninfectious) clinically significant interstitial lung disease (ILD)/pneumonitis that required , active clinically significant ILD/pneumonitis, or suspected clinically significant ILD/pneumonitis that cannot be ruled out by imaging at screening.
  14. Requires supplemental oxygen for daily activities
  15. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
  16. Combination Specific Exclusion Criteria:

To be eligible to participate in the combination arms of the study, participants must not meet the combination specific exclusion criteria in addition to the general exclusion criteria.

to cemiplimab or any of its excipients or to cemiplimab per approved local labeling.

Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).

Prior allogeneic stem cell or solid organ transplantation.

Patients with history of myocarditis.

Presence of cardiovascular disease, as defined by:

New York Heart Association heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or

or stroke within 1 year.

Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    BHV-1530 Monotherapy

    Drug: BHV-1530

  • Experimental
    Experimental: BHV-1530 in combination with Cemiplimab

    Drug: BHV-1530 · Drug: Cemiplimab

Interventions

  • DrugBHV-1530

    BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle

    Also known as: AMB302

  • cemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Dose-escalation and Dose-expansion Cohorts: To determine the safety profile, maximum tolerable dose (MTD), minimally reproducible active dose (MRAD), and recommended dose range (RDR) of BHV-1530 monotherapy and BHV-1530 in combination with cemiplimab

    Incidence and severity of TEAEs, including DLTs, SAEs and change from baseline for laboratory values, electrocardiograms (ECGs), vital signs, and physical exams to determine the safety profile, MTD, MRAD and RDR of BHV-1530 monotherapy and in combination with cemiplimab.

    Time frame: Through study completion, estimated as an average of 48 months

  2. Dose-optimization Cohorts: Recommended dose of BHV-1530 for later phase trials

    Incidence and severity of treatment-emergent AEs and SAEs, changes between baseline and postbaseline in laboratory values, ECGs, vital signs, and physical exams.

    Time frame: Through study completion, estimated as an average of 48 months

Secondary outcomes

  1. Dose-escalation and Dose-expansion Cohorts: Clinical Benefit Rate (CBR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  2. Dose-escalation and Dose-expansion Cohorts: Objective Response Rate (ORR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  3. Dose-escalation and Dose-expansion Cohorts: Disease Control Rate (DCR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  4. Dose-escalation and Dose-expansion Cohorts: Time to Response (TTR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  5. Dose-escalation and Dose-expansion Cohorts: Duration of Response (DOR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  6. Dose-escalation and Dose-expansion Cohorts: Progression-free Survival (PFS)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  7. Dose-escalation and Dose-expansion Cohorts: Maximum observed serum concentration (Cmax)

    Serum concentration of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  8. Dose-escalation and Dose-expansion Cohorts: Time of maximum concentration (Tmax)

    Time of maximum concentration of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  9. Dose-escalation and Dose-expansion Cohorts: Elimination half-life (t½)

    Terminal elimination half-life (t½) of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  10. Dose-escalation and Dose-expansion Cohorts: Area Under the Concentration versus time curve (AUC)

    Area under the concentration-time curve from zero to last quantifiable concentration (AUC0-t) and AUC extrapolated to infinity (AUC0-inf) and AUC over the dosing interval (AUCtau)

    Time frame: Through study completion, estimated as an average of 48 months

  11. Dose-escalation and Dose-expansion Cohorts: Trough concentration (Ctrough)

    Trough concentration of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  12. Dose-escalation and Dose-expansion Cohorts: Total body clearance (CL)

    Total body clearance of BHV-1530 and total antibody

    Time frame: Through study completion, estimated as an average of 48 months

  13. Dose-escalation and Dose-expansion Cohorts: Volume of distribution at steady state (Vss)

    Volume of distribution of BHV-1530 and total antibody

    Time frame: Through study completion, estimated as an average of 48 months

  14. Dose-optimization Cohorts: Objective Response Rate (ORR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  15. Dose-optimization Cohorts: Disease Control Rate (DCR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  16. Dose-optimization Cohorts: Time to Response (TTR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  17. Dose-optimization Cohorts: Duration of Response (DOR)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  18. Dose-optimization Cohorts: Progression-free Survival (PFS)

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 48 months

  19. Dose-optimization Cohorts: Maximum observed serum concentration (Cmax)

    Serum concentration of BHV-1530, total antibody and free payload TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  20. Dose-optimization Cohorts: Time of maximum concentration (Tmax)

    Time of maximum concentration of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  21. Dose-optimization Cohorts: Elimination half-life (t½) of BHV-1530

    Terminal elimination half-life (t½) of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  22. Dose-optimization Cohorts: Area Under the Concentration versus time curve (AUC)

    Area under the concentration-time curve from zero to last quantifiable concentration (AUC0-t) and AUC extrapolated to infinity (AUC0-inf) and AUC over the dosing interval (AUCtau)

    Time frame: Through study completion, estimated as an average of 48 months

  23. Dose-optimization Cohorts: Trough concentration (Ctrough)

    Trough concentration of BHV-1530, total antibody and TopoIx BHV-0080269

    Time frame: Through study completion, estimated as an average of 48 months

  24. Dose-optimization Cohorts: Total body clearance (CL)

    Total body clearance of BHV-1530 and total antibody

    Time frame: Through study completion, estimated as an average of 48 months

  25. Dose-optimization Cohorts: Volume of distribution at steady state (Vss)

    Volume of distribution of BHV-1530 and total antibody

    Time frame: Through study completion, estimated as an average of 48 months

07

Study locations

16 of 17 sites recruiting
  • Site-111
    Newport Beach, California 92663, United States
    Recruiting
  • Site-107
    Denver, Colorado 80218, United States
    Recruiting
  • Site-108
    Lake Mary, Florida 32746, United States
    Withdrawn

    Not enrolling at this site.

  • Site-121
    Miami, Florida 33136, United States
    Recruiting
  • Site-118
    Orlando, Florida 32804, United States
    Recruiting
  • Site-120
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Site-110
    Detroit, Michigan 48201, United States
    Recruiting
  • Site-115
    Durham, North Carolina 27710, United States
    Recruiting
  • Site-122
    Cleveland, Ohio 44195, United States
    Recruiting
  • Site-112
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Site-116
    Nashville, Tennessee 37203, United States
    Recruiting
  • Site-103
    Austin, Texas 78758, United States
    Recruiting
  • Site-104
    Houston, Texas 77030, United States
    Recruiting
  • Site-101
    Irving, Texas 75039, United States
    Recruiting
  • Site-105
    San Antonio, Texas 78229, United States
    Recruiting
  • Site-106
    West Valley City, Utah 84119, United States
    Recruiting
  • Site-102
    Fairfax, Virginia 22031, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 13, 2025
StartActual
Mar 20, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06874335
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
Mar 20, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Chief Medical Officer
Contact
clinicaltrials@biohavenpharma.com
203-404-0410

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion